CD8A and neoplasm: designed a nanoemulsion (NE) based formulation loading with the TLR7/8 agonists (NE (TLR7/8a)), which could repolarize M2‐like TAMs into M1‐like ones and inhibit B16F10 tumor growth to prolong the survival of tumor‐bearing mice.[97] Additionally, local administration of NE (TLR7/8a) with tumor antigens could also induce CD8+ T cell and NK1.1+ cell immunity and improve the efficacy of anti‐PD‐L1 therapy.